MENU

We're on a mission to add five great years to the lives of a million older Americans.

CopilotIQ started with a belief that there is a desperate need to transform how care is delivered to those suffering from diabetes and hypertension.



 

We set out to solve three fundamental problems:

  • You can’t fix chronic conditions with episodic care. You need to treat these conditions longitudinally, and with high frequency to drive needed change.
  • You can’t prevent problems you can’t see. You need 1,000 times more data to identify issues before they become a crisis.
  • There are not enough (and will never be enough) physicians to adequately care for the population. There are less than 9,000 endocrinologists in the U.S. to serve 100 million diabetics and pre-diabetics.
Active Members
0 +
Clinicians
0 +
States Served
0

About CopilotIQ

CopilotIQ combines high-frequency care with US-based and licensed nurses, with connected devices that capture 1,000 times the data, and an AI-driven software platform called remoteIQ to transform how we manage care. 



 

Our platform is designed to help older Americans with chronic conditions live longer, healthier lives.

Merger Announcement

CopilotIQ and Biofourmis merge to create the first end-to-end platform for AI-driven in-home care. 

Learn More

Americans Are Losing 5 Years to Chronic Conditions

90% of all healthcare costs in the U.S. are allocated to treating chronic diseases and mental health conditions.¹

Chronic conditions among older Americans are exploding, with diabetes growing 72% in the past three decades and impacting over 29% of the 65+ population.⁵

Hypertension now affect 70% of everyone 65+.⁴

It accounts for 81% of all hospital admissions, and five lost years compared to other developed nations.

Source: healthsystemtracker.org

Nearly $500 Billion in Cost by 2030²

Nearly one in every two healthcare dollars for older Americans is spent on diabetes and hypertension.



 

We are spending the most per capita of any nation, and yet have among the worst outcomes.



 

The solution lies with a much greater focus on preventative care, driving reduced hospitalizations, reduced medication spending, and better outcomes.


Introducing High-Frequency Connected Care

Gearing up
Members receive a cellular-connected blood pressure cuff, glucose meter, and scale as needed to take daily readings. The data drives accountability, and enables us to track progress and spot issues early.
Consistent Communication
CopilotIQ members receive regular one-on-one sessions with a US-based licensed nurse. The dedicated nurse works on nutritional guidance, medication adherence, personalized exercise plans, and lifestyle changes. Our goal is to drive the best members outcomes at the lowest possible cost to the system.
Cutting-Edge Technology
By leveraging our proprietary software platform, we combine 1,000 times more biomarker data with real-time monitoring and alerts. Our platform drives actionable insights also enables our clinical team to more efficiently deliver care.

Delivering Transformative Clinical Outcomes

Average % Change in Fasting Glucose by Week from First Reading³

  • CopilotIQ members that joined with a fasting glucose levels above 300 achieved an average reduction of 52.8% in 26 weeks.³

  • 89% of patients that started in hypertensive crisis exit in the first 13 weeks.³

  • Life-threatening hypoglycemia and hyperglycemia events were reduced by nearly 50% and 38%, respectively, leading to fewer hospitalizations and ER visits.³

  • 43% of patients with Stage 2 Hypertension achieved at least one stage reduction in blood pressure within the first three months of joining the program.³

Meet Our Team

We built a world-class team with deep expertise in AI, software, and healthcare. We’re all unified by a single goal: to add five great years to the lives of our members.

Leadership

David Koretz

Chief Executive Officer

Steven McKenzie

Chief Revenue Officer

Maulik Majmudar

Chief Medical Officer

AJ Ruiz

Chief People Officer

Raghu Mallena

Chief Technology Officer

Clinical Advisory Board

Dr. Mark Rice
Dr. Mark Rice

Executive Vice Chairman, Anesthesiology
Vanderbilt Medical Center

Dr. Alex Gelbard

Vice Chair of Research

Department of Otolaryngology

UVMC

Dr.-Greene
Dr. Alice Greene

Former Lead Physician,

GoodRx


MD University of Pennsylvania

Board of Directors

David Koretz​

CopilotIQ & Biofourmis

Andrew Hedin

Bessemer Venture Partners

Jeff Clarke

Doxim

Ben Wanamaker

General Atlantic

Shane Chesson

Openspace Ventures

Let's Work Together

Join us to help solve one of the largest societal problems of our time.

Apply Now

Citations and Footnotes

¹ Benavidez GA, Zahnd WE, Hung P, Eberth JM. Chronic Disease Prevalence in the US: Sociodemographic and Geographic Variations by Zip Code Tabulation Area. Prev Chronic Dis 2024;21:230267. DOI: http://dx.doi.org/10.5888/pcd21.230267

² Rowley WR, Bezold C, Arikan Y, Byrne E, Krohe S. Diabetes 2030: Insights from Yesterday, Today, and Future Trends. Popul Health Manag. 2017 Feb;20(1):6-12. doi: 10.1089/pop.2015.0181. Epub 2016 Apr 28. PMID: 27124621; PMCID: PMC5278808.

³ Internal Research Study, CopilotIQ, March 2023.

⁴ Leszczak J, Czenczek-Lewandowska E, Asif M, Baran J, Mazur A, Wyszyńska J. Risk factors and prevalence of hypertension in older adults from south-eastern Poland: an observational study. Sci Rep. 2024 Jan 16;14(1):1450. doi: 10.1038/s41598-024-52009-3. PMID: 38228769; PMCID: PMC10792009.

⁵ Centers for Disease Control and Prevention. National Diabetes Statistics Report website. https://www.cdc.gov/diabetes/php/data-research/index.html. Accessed 05/29/2024